Xeris Biopharma (NSDQ:XERS) announced today that it entered into a securities purchase agreement in connection with a private placement. Chicago-based Xeris’ private placement with an affiliate of Armistice Capital, LLC, will provide aggregate gross proceeds totaling approximately $30 million. The company will issue Armistice more than 10.2 million shares of its common stock at a […]
Xeris Pharmaceuticals
Xeris enters collaboration with Merck
Xeris Biopharma (NSDQ:XERS) announced today that it entered into a collaboration agreement with Merck (NYSE:MRK) for its XeriJect technology. Chicago-based Xeris’ collaboration with Merck includes an option to license the XeriJect suspension-based formulation technology for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations. The financial terms of the […]
FDA approves supplemental new drug application for Xeris’ hypoglycemia treatment
Xeris Pharmaceuticals (NSDQ:XERS) announced today that the FDA approved its supplemental new drug application for the Gvoke kit. Chicago-based Xeris’ Gvoke (Ogluo in Europe) a ready-to-use pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia for people with diabetes ages 2 and above. The kit will be available as a 1 mg/0.2 mL single dose vial […]
Xeris reaches payor coverage milestone for glucagon injection
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it achieved a milestone for the payor coverage of its Gvoke glucagon injection. Approximately 91% of Medicare patients, 88% of commercially insured patients and a growing number of Medicaid lives have unrestricted access to Gvoke, Xeris said in a news release. Chicago-based Xeris’ Gvoke, a ready-to-use pre-mixed, pre-measured glucagon […]
Xeris, Tetra Pharma enter $71M licensing agreement for glucagon injection
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it entered into an exclusive agreement with Tetris Pharma to commercialize Ogluo. Chicago-based Xeris designed Ogluo (Gvoke PFS and Gvoke HypoPen in the U.S.) to be a ready-to-use, pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia in adults, adolescents and children two years of age and older with diabetes […]
